Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis
Abstract Background Interleukin-6-receptor inhibitors like Tocilizumab and Satralizumab are showing promising results in the treatment of Neuromyelitis Optica spectrum disorder (NMOSD). We aimed to investigate the efficacy and safety of various Interleukin-6-receptor inhibitors in the management of...
Enregistré dans:
Auteurs principaux: | Sanjeev Kharel, Suraj Shrestha, Rajeev Ojha, Neha Guragain, Rakesh Ghimire |
---|---|
Format: | article |
Langue: | EN |
Publié: |
BMC
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/f636e8b70e004c17b9339b5d2b02f9fa |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Area postrema syndrome in neuromyelitis optica spectrum disorder: diagnostic challenges and descriptive patterns
par: Eman M. Khedr, et autres
Publié: (2021) -
Cytokines and chemokines expression in serum of patients with neuromyelitis optica
par: Ai NP, et autres
Publié: (2019) -
Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations
par: Han J, et autres
Publié: (2017) -
Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder
par: Bo Chen, et autres
Publié: (2017) -
The role of interleukin-24 in atopic dermatitis
par: Yen Hai Vu, et autres
Publié: (2021)